PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals (US) today announced that it will be presenting five company-sponsored abstracts at the 2019 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo taking place on October 12-16, 2019, in Philadelphia, Pennsylvania.
Ferring’s first oral presentation will highlight data from MEGASET-HR, which evaluates gonadotropin related differences in follicle endocrine physiology in predicted high responder women undergoing assisted reproductive technology. The second oral presentation will cover study results revealing the impact of body weight on ovarian response after individualized or fixed follicle-stimulating hormone dosing in women undergoing ovarian stimulation for IVF.
Additionally, the company will be sharing three poster presentations at the congress, one of which examines the cost difference of fertility treatment with highly purified-human menotropin (HP-hMG) in comparison to recombinant follicle stimulating hormone (rFSH) for a predicted high responder population. The second identifies the gap and factors that cause a discrepancy between the potential for and the utilization of fertility care in the U.S. The final poster will be presenting results from a global study about a randomized, double-blind, placebo-controlled, multi-center, phase II trial to investigate the effect of a selective oxytocin antagonist barusiban on implantation in IVF/ICSI patients.
“We are excited to present these findings at the 2019 ASRM congress, where leaders in reproductive medicine have been sharing ground-breaking data for 75 years,” said Gaurang Daftary, M.D., M.B.A, Senior Medical Director, Ferring Pharmaceuticals. "At Ferring, we look to advance research in the field of reproductive medicine and maternal health with the goal of developing the most innovative products in this important therapeutic area.”
Details for the presentations are as follows:
Poster (P-282):
Title: Can Treatment Choice Affect Cost of Therapy in Patients Predicted to be High-Responders? Results of an Economic Analysis of the MENOPUR in GnRH Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) Trial
Date, Time and Location: Tuesday, October 15, 2019; 6:30AM-7:45AM in Expo Hall
Poster (P-3):
Title: Patient Access and Untapped Potential: Can New Data Drive Progress?
Date, Time and Location: Tuesday, October 15, 2019; 6:30AM-7:45AM in Expo Hall
Poster (P-182):
Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Trial to Investigate the Effect of Barusiban on Implantation in IVF/ICSI Patients
Date, Time and Location: Tuesday, October 15, 2019; 6:30AM-7:45AM in Expo Hall
Oral (O-133):
Title: Gonadotropin-Specific Follicular Steroidogenesis in Ovarian Stimulation: Evidence from the MENOPUR in GnRH Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) Trial
Date, Time and Location: Tuesday, October 15, 2019; 10:45AM in Ballroom AB
Oral (O-211):
Title: Impact of Body Weight on Ovarian Response After Individualized or Fixed Follicle-Stimulating Hormone Dosing in Women Undergoing Ovarian Stimulation for In Vitro Fertilization
Date, Time and Location: Wednesday, October 16, 2019; 10:45AM-11:00AM in 103C
For more information on the abstracts, visit asrmcongress.org/ or download the ASRM Events Gateway mobile application here to view the posters in real-time.
Menopur® Indication
Menopur (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program.
Important Safety Information
Menopur is contraindicated in women who have: a high FSH level indicating primary ovarian failure, presence of uncontrolled non-gonadal endocrinopathies, tumors of the pituitary gland or hypothalamus, sex hormone dependent tumors of the reproductive tract and accessory organs, abnormal uterine bleeding of undetermined origin, ovarian cysts or enlargement of undetermined origin, not due to polycystic ovary syndrome, or prior hypersensitivity to menotropins or MENOPUR. MENOPUR is not indicated in women who are pregnant and may cause fetal harm when administered to a pregnant woman.
Menopur should only be used by physicians who are thoroughly familiar with infertility problems. Menopur is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Ovarian torsion has been reported after gonadotropin treatment. Serious pulmonary conditions and thromboembolic events have been reported with Menopur. There have been infrequent reports of ovarian neoplasms with Menopur. Multiple pregnancies, spontaneous abortion, congenital malformations and ectopic pregnancies have occurred following treatment with Menopur.
The most common adverse reactions (≥2%) in ART include: abdominal cramps; abdomen enlarged; abdominal pain; headache; injection site pain and reaction; injection site inflammation; OHSS.
Please see here for full Prescribing Information for Menopur.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive medicine, maternal health, urology, gastroenterology, endocrinology, oncology, and orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com.
